OncoPep is developing novel immunotherapeutics aimed at preventing cancer progression, extending survival, and restoring patients' quality of life. Its lead program, PVX-410, is an investigational multi-peptide therapeutic vaccine being evaluated in smoldering multiple myeloma (SMM) and triple-negative breast cancer (TNBC). OncoPep says PVX-410 stimulates an immune response against cancer cells. The company will use the Series D proceeds to continue clinical trials and to advance preclinical development of novel pipeline agents. OncoPep is pursuing both clinical and preclinical programs to expand its pipeline. The company is based in Cambridge, MA. OncoPep is developing targeted immunotherapeutics with a lead multi-peptide therapeutic vaccine, PVX-410, for smoldering multiple myeloma. PVX-410 is designed to target tumor antigens associated with multiple myeloma and received orphan drug designation from the U.S. FDA in 2013. The company is conducting an open-label Phase 1/2a dose-escalation study to evaluate safety and tolerability of PVX-410 alone and in combination with lenalidomide; secondary endpoints measure immune and clinical responses. To date, 12 patients have been treated with vaccine alone, and the trial has been expanded to a second arm adding concurrent courses of lenalidomide. Dosing in the escalation arm included 0.4 mg or 0.8 mg administered as six bi-weekly subcutaneous injections over 10 weeks with the adjuvant poly ICLC; combo-arm patients receive 0.8 mg plus three 21-day courses of oral lenalidomide. Proceeds from the recent financing will support continued clinical development of PVX-410 across multiple U.S. cancer centers. OncoPep was founded in 2010 and is based in North Andover, MA. The company exclusively licensed proprietary core technology from the Dana Farber Cancer Institute developed in Dr. Kenneth Anderson’s laboratory. Its platform uses a unique combination of proprietary peptides and adjuvants to form therapeutic cancer vaccines designed to stimulate a patient’s immune system to attack cancer. OncoPep’s lead program, PVX-410, is a multi-peptide therapeutic vaccine targeting antigens on multiple myeloma cells, with an initial clinical target of smoldering multiple myeloma. The company planned to initiate a Phase 1 trial in the U.S. for PVX-410 in 2012. Recently it raised $2.525 million in venture capital, disclosed in an SEC filing.

Total raised

$20M

Funding rounds

3

Latest round

Series D

Latest activity

Dec 2021